EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Apontis Pharma AG's enterprise value is €51.11 Mil.
Apontis Pharma AG's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was €36.96 Mil. Therefore, Apontis Pharma AG's EV-to-Revenue for today is 1.38.
The historical rank and industry rank for Apontis Pharma AG's EV-to-Revenue or its related term are showing as below:
XTER:APPH'
s EV-to-Revenue Range Over the Past 10 Years
Min: -0.18 Med: 1.05 Max: 5.36
Current: 1.38
During the past 6 years, the highest EV-to-Revenue of Apontis Pharma AG was 5.36. The lowest was -0.18. And the median was 1.05.
XTER:APPH's EV-to-Revenue is ranked better than 68.27% of 1018
companies
in the Drug Manufacturers industry
Industry Median: 2.21
vs XTER:APPH: 1.38
The historical data trend for Apontis Pharma AG's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Apontis Pharma AG's EV-to-Revenue
For the Drug Manufacturers - Specialty & Generic subindustry, Apontis Pharma AG's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Apontis Pharma AG's EV-to-Revenue Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Apontis Pharma AG's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Apontis Pharma AG's EV-to-Revenue falls into.
Apontis Pharma AG's current Enterprise Value is €51.11 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Apontis Pharma AG's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was €36.96 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Apontis Pharma AG (XTER:APPH) EV-to-Revenue Explanation
Apontis Pharma AG's share price for today is €8.66.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2023 was €4.35.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Apontis Pharma AG EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Apontis Pharma AG's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Apontis Pharma AG (XTER:APPH) Business Description
Apontis Pharma AG is a pharmaceutical company specializing in single pills in Germany. single pills combine two to three generic active ingredients in a single dosage form. The company develops, promotes, and sells a broad portfolio of single pills and other pharmaceutical products, with a special focus on cardiovascular diseases.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XTER:APPH has been successfully added to your 